Related Experiment Video
Updated: Aug 5, 2026
08:56
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
Published on: July 12, 2022
CDK4/6 Inhibitor-Induced Senescence in Cancer: Mechanisms and Therapeutic Implications
Simin Elif Türker1, Marco Demaria1, Boshi Wang1
1European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG), University of Groningen (RUG), 9713 AV Groningen, The Netherlands.
Cancers
|July 28, 2026
Summary
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors induce cellular senescence, a state of stable cell cycle arrest. This process influences tumor suppression and microenvironment remodeling, presenting therapeutic opportunities and challenges.
Area of Science:
- Oncology
- Cell Biology
- Cancer Therapeutics
Background:
- Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are established treatments for HR+/HER2- breast cancer.
- These inhibitors enforce G1-S cell cycle arrest by preventing retinoblastoma (RB) phosphorylation, leading to tumor control.
- Prolonged CDK4/6 inhibition induces cellular senescence, a stable proliferative arrest with significant cellular changes.
Purpose of the Study:
- To review current knowledge on CDK4/6 inhibitor-induced senescence.
- To explore the role of senescence in tumor suppression and microenvironmental remodeling.
- To discuss resistance mechanisms and combination strategies for CDK4/6 inhibitors.
Main Methods:
- Literature review of CDK4/6 inhibitor-induced senescence.
- Analysis of senescence in cancer and normal cells.
- Examination of the senescence-associated secretory phenotype (SASP).
Main Results:
- CDK4/6 inhibitor-induced senescence is context-dependent, differing between tumor and normal cells.
- Senescence influences the tumor microenvironment by modulating immune surveillance, stromal interactions, and cancer cell plasticity.
- Distinct SASP profiles impact immune responses and tissue homeostasis.
Conclusions:
- CDK4/6 inhibitor-induced senescence is a key mechanism linking tumor suppression and microenvironment modulation.
- Understanding senescence is crucial for developing effective combination therapies and overcoming resistance.
- Integrating cell cycle control with senescence modulation offers therapeutic potential.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.